THE US Food and Drug
Administration (FDA) has approved
Epclusa to treat adult patients with
chronic hepatitis C virus (HCV) both
with and without cirrhosis.
Epclusa is a fixed-dose
combination tablet containing
sofosbuvir, a drug approved in the
US in 2013, and velpatasvir, a new
drug, and is the first to treat all six
major forms of HCV.The above article was sent to subscribers in Pharmacy Daily's issue from 30 Jun 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Jun 16
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.